13F
← All fund report cards

Prime Capital Investment Advisors, LLC

13F equity value
$8.6B
Positions
1,025
Top 10 concentration
26.4%
Quarters / total new picks
31 / 1,473
13F equity value over time
$0M$4B$9B2017201820192020202120222023202420252026

"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.

Not significant Verdict

13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.

We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 31 quarters, returned +2.3% per quarter — versus +2.6% per quarter from simply owning every 13F stock. It beat that baseline in only 45.2% of quarters (excess t = 1.26, not statistically significant). Its filings tell you what it bought — not what you should buy.

Avg 2Q excess
+1.6%
t-stat
1.26
Quarterly win rate
45%
Annualized excess
-1.8%
$1 → follow vs universe
$1.71 vs $1.94
Cumulative return: $1 invested in new picks vs universe
1.00 20180331: universe 1.04120180630: universe 0.95920180930: universe 1.00320181231: universe 0.99220190331: universe 0.97520190630: universe 1.04820190930: universe 1.12720191231: universe 0.90920200331: universe 1.09620200630: universe 1.21120200930: universe 1.48520201231: universe 1.55320210331: universe 1.56620210630: universe 1.69220210930: universe 1.51920211231: universe 1.29220220630: universe 1.19720220930: universe 1.28620221231: universe 1.19420230331: universe 1.25820230630: universe 1.21320230930: universe 1.37720231231: universe 1.43920240331: universe 1.47120240630: universe 1.60520240930: universe 1.59120241231: universe 1.48520250331: universe 1.61920250630: universe 1.67020250930: universe 1.87820251231: universe 1.942 20180331: follow 1.04220180630: follow 0.98620180930: follow 0.98520181231: follow 0.95620190331: follow 0.94420190630: follow 0.98520190930: follow 1.07320191231: follow 0.77920200331: follow 0.94220200630: follow 1.15420200930: follow 1.40420201231: follow 1.30120210331: follow 1.39120210630: follow 1.46320210930: follow 1.26620211231: follow 1.27420220630: follow 1.22020220930: follow 1.26320221231: follow 1.21920230331: follow 1.24520230630: follow 1.22820230930: follow 1.36420231231: follow 1.45020240331: follow 1.45820240630: follow 1.68420240930: follow 1.59120241231: follow 1.37720250331: follow 1.47820250630: follow 1.48720250930: follow 1.70820251231: follow 1.707 0.72 1.41 2.10 20182019202020212022202320242025 Follow Universe

Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)

Listed as facts. See the verdict above before treating this as signal.

Top 20 holdings of 1025 · 2026 Q1

Ticker Value Weight QoQ
AGG $365M
4.2%
TRIM
VTI $348M
4.0%
TRIM
IVV $305M
3.5%
ADD
ITOT $230M
2.7%
ADD
SCHX $228M
2.6%
TRIM
AAPL $198M
2.3%
TRIM
NVDA $197M
2.3%
HOLD
VGK $159M
1.8%
TRIM
VTV $133M
1.5%
TRIM
VOO $122M
1.4%
HOLD
MSFT $120M
1.4%
TRIM
FESM $118M
1.4%
ADD
QQQ $118M
1.4%
HOLD
SCHF $110M
1.3%
TRIM
AMZN $107M
1.2%
TRIM
BND $103M
1.2%
ADD
SPY $102M
1.2%
ADD
IXUS $101M
1.2%
HOLD
DGRW $95M
1.1%
TRIM
VTEB $95M
1.1%
HOLD

QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.

Listed as facts. See the verdict above before treating this as signal.

New positions in 2026 Q1

Method & Limitations

Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.